Price (delayed)
$18.69
Market cap
$915.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$791.72M
Highlights
The company's quick ratio has surged by 101% YoY and by 15% QoQ
ELVN's equity is up by 26% YoY and by 7% QoQ
The company's net income fell by 24% YoY and by 4.5% QoQ
Key stats
What are the main financial stats of ELVN
MarketValuationsEarnings
Shares outstanding
49M
Market cap
$915.89M
Enterprise value
$791.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.95
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$104.55M
Net income
-$89.02M
EBIT
-$88.79M
EBITDA
-$88.16M
Free cash flow
-$73.24M
Per shareBalance sheetLiquidity
EPS
-$1.89
EPS diluted
-$1.89
Free cash flow per share
-$1.56
Book value per share
$6.34
Revenue per share
$0
TBVPS
$6.92
Total assets
$325.76M
Total liabilities
$15.92M
Debt
$0
Equity
$309.85M
Working capital
$302.21M
Debt to equity
0
Current ratio
19.99
Quick ratio
19.7
Net debt/EBITDA
1.41
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.4%
Return on equity
-29.2%
Return on invested capital
-47.4%
Return on capital employed
-28.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELVN stock price
How has the Enliven Therapeutics stock price performed over time
Intraday
-6.69%
1 week
-11.3%
1 month
-6.17%
1 year
0.48%
YTD
-16.93%
QTD
-5.03%
Financial performance
How have Enliven Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$104.55M
Net income
-$89.02M
Gross margin
N/A
Net margin
N/A
ELVN financials
Enliven Therapeutics's operating income has decreased by 25% YoY and by 4.2% QoQ
The company's net income fell by 24% YoY and by 4.5% QoQ
Growth
What is Enliven Therapeutics's growth rate over time
ELVN growth chart
Valuation
What is Enliven Therapeutics stock price valuation
P/E
N/A
P/B
2.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
Enliven Therapeutics's EPS has increased by 6% YoY
Price to book (P/B)
ELVN's equity is up by 26% YoY and by 7% QoQ
ELVN's P/B is 18% above its 5-year quarterly average of 2.5 but 13% below its last 4 quarters average of 3.4
Price to sales (P/S)
Efficiency
How efficient is Enliven Therapeutics business performance
ELVN's return on invested capital is up by 19% year-on-year
The return on equity has declined by 10% year-on-year
Enliven Therapeutics's ROA has decreased by 9% YoY
Dividends
What is ELVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELVN.
Financial health
How did Enliven Therapeutics financials performed over time
Assets vs liabilities
The company's quick ratio has surged by 101% YoY and by 15% QoQ
The current ratio has soared by 94% YoY and by 15% from the previous quarter
Debt vs equity
The debt is 100% less than the equity
ELVN's equity is up by 26% YoY and by 7% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.